Iterum Therapeutics PLC (ITRM) Loses 67.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 07/29/21
Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral SulopenemGlobeNewsWire • 07/26/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iterum Therapeutics plc (ITRM)PRNewsWire • 07/07/21
Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative BuySeeking Alpha • 07/05/21